L

LSL Pharma Group Inc
XTSX:LSL

Watchlist Manager
LSL Pharma Group Inc
XTSX:LSL
Watchlist
Price: 0.42 CAD 2.44% Market Closed
Market Cap: CA$53.2m

LSL Pharma Group Inc
Deferred Income Tax

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

LSL Pharma Group Inc
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
L
LSL Pharma Group Inc
XTSX:LSL
Deferred Income Tax
CA$1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Deferred Income Tax
$147m
CAGR 3-Years
-10%
CAGR 5-Years
-23%
CAGR 10-Years
-31%
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Deferred Income Tax
CA$3m
CAGR 3-Years
-12%
CAGR 5-Years
-33%
CAGR 10-Years
31%
Spectral Medical Inc
TSX:EDT
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipher Pharmaceuticals Inc
TSX:CPH
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

LSL Pharma Group Inc
Glance View

Market Cap
53.2m CAD
Industry
N/A

LSL Pharma Group, Inc. operates as a pharmaceutical company. The company is headquartered in Boucherville, Quebec. The company went IPO on 2011-03-08. The firm specializes in the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms. The firm is also engaged in selling sterile ophthalmic pharmaceutical products.

LSL Intrinsic Value
0.45 CAD
Undervaluation 6%
Intrinsic Value
Price CA$0.42
L

See Also

What is LSL Pharma Group Inc's Deferred Income Tax?
Deferred Income Tax
1.8m CAD

Based on the financial report for Dec 31, 2024, LSL Pharma Group Inc's Deferred Income Tax amounts to 1.8m CAD.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett